Recent Updates — DWTX

Dogwood Therapeutics closed a $5 million private placement with Sealbond Limited, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc., to advance Phase 3 preparatory activities for its lead candidate Halneuron and for working capital. The company reported a third-quarter net loss attributable to common stockholders of $4.9 million, or $0.14 per share, compared to a $15.7 million loss in the prior-year period. Research and development expenses decreased by $11.2 million year-over-year due to lower acquired in-process research and development costs. Cash on hand combined with the new funding provides an operational runway through the first quarter of 2027. The company is a biopharmaceutical firm developing non-opioid medicines for pain and neuropathy.

Dogwood Therapeutics entered into a subscription agreement to issue and sell 4,098,360 shares of common stock in a private placement to Sealbond Limited, an affiliate of largest shareholder CK Life Sciences Int’l., (Holdings) Inc. The shares were sold at $1.22 per share, generating approximately $5 million in gross proceeds before offering expenses. The transaction is expected to close on or prior to October 29, 2026. Dogwood intends to use the net proceeds for Phase 3 preparatory activities for its lead drug candidate Halneuron®, as well as general working capital and corporate purposes. This investment extends the company's operational runway through March 2027. Dogwood Therapeutics is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders.

Dogwood Therapeutics reported a net loss of $11.5 million for the second quarter ended June 30, 2026, or $0.34 per share, driven by a $9.2 million non-cash IPR&D impairment charge and increased R&D expenses of $3.2 million. The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million to Dogwood and its CVR holders. Halneuron Phase 2b trial enrollment reached 217 patients, with top-line results expected in fall 2026, while SP16 received FDA IND approval for a fully NCI-funded Phase 1b study beginning in the second half of 2026. Cash on hand stands at $9.6 million, providing runway through the fourth quarter 2026. Dogwood Therapeutics is a biopharmaceutical company developing non-opioid medicines to treat pain and neuropathic disorders.

At its annual meeting on June 16, 2026, Dogwood Therapeutics, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common and preferred stock. The meeting also resulted in the following voting results: election of seven directors, ratification of Forvis Mazars, LLP as independent auditor, and approval of advisory votes on executive compensation frequency and compensation. Dogwood Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for various medical conditions.